Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

doi:10.1016/j.lungcan.2016.06.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2016

Cappuzzo Federico, Morabito Alessandro, Normanno Nicola, Bidoli Paolo, Del Conte Alessandro, Giannetta Laura, Montanino Agnese, Mazzoni Francesca, Buosi Roberta, Burgio Marco Angelo, Cerea Giulio, Chiari Rita, Cortinovis Diego, Finocchiaro Giovanna, Foltran Luisa, Migliorino Maria Rita, Tiseo Marcello, Ferrari Silvia, De Marinis Filippo

Abstract excerpt

OBJECTIVES: Although patients with advanced non-small cell lung cancer (NSCLC) and an activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR-tyrosine kinase inhibitors (TKI), most of them progress within 12 months from treatment start due to acquired resistance. In clinical practice, many physicians frequently offer these patients retreatment with EGFR-TKIs after a chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quality of Life

Share to Quinazolines

Share to Retreatment

Source

Open in PubMed

Identifiers

PMID: 27565910
DOI: 10.1016/j.lungcan.2016.06.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.PMID 27565910Read ↗

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.Semantic proximity Read ↗

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.Semantic proximity Read ↗

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.Semantic proximity Read ↗

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.Semantic proximity Read ↗

Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.